Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
about
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemicCurrent Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with ThiazolidinedionesPleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future PerspectivesTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDCurrent Management of NAFLDAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentNon-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatmentResidual macrovascular risk in 2013: what have we learned?Nonalcoholic fatty liver disease: new treatmentsThe impact of PPARα activation on whole genome gene expression in human precision cut liver slicesPPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Evolving targets for lipid-modifying therapyExercise training improves liver steatosis in micePPARs and Mitochondrial Metabolism: From NAFLD to HCC.Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.Pharmacological agents for NASH.Evolving therapies for non-alcoholic steatohepatitis.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Nonalcoholic fatty liver disease - current status and future directions.Review article: new treatments in non-alcoholic fatty liver disease.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp.Treatment options for nonalcoholic steatohepatitis - a safety evaluation.Current and future pharmacologic treatment of nonalcoholic steatohepatitis.Management of NAFLD: a stage-based approach.Current and future treatment options in non-alcoholic steatohepatitis (NASH).The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.The role of macrophages in obesity-driven chronic liver disease.Nuclear receptors and nonalcoholic fatty liver disease.Therapies in non-alcoholic steatohepatitis (NASH).Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
P2860
Q24563381-95D2AF3B-B5DD-4ED1-B9D5-728B507BB5B6Q26745533-0A4074B5-FBEE-454F-A46A-81D67278CB25Q26747009-BCDF686E-5F68-44F2-9D66-7960CEB9EB5BQ26751258-4D526AA3-5FDD-4394-9F24-19F9DEDF9A9DQ26752487-C40C77F6-7B87-4024-9582-CE8863EE5A72Q26752729-18AA4160-8A2C-48AF-992D-30F59072A628Q26830274-032F158A-C3D4-45BF-8DA8-4BF45AA5AA60Q26852019-42B6B663-D2AA-4A75-9586-00E37E30DEC7Q26996039-EF827C1B-DE0F-46AF-B825-5D1573EFC012Q27021161-95D28D6A-EF11-4B45-9829-A3AED3471115Q28606579-A99A8C0D-11A8-41BE-AF0A-24E1F021006EQ30241952-045098BD-7008-457D-BFF3-D9830EA27316Q34041838-30987B88-BD46-49CB-8C8B-DB6A89B6E7DBQ34041987-592DC505-962C-49A5-B400-B3FC9175AB63Q34398065-F7B740EF-DBA5-4D12-8311-59AB85EB0E87Q34422821-6B88DA28-F77F-4EF9-9E91-DF8C61D06E49Q34540703-3215A8E5-B4ED-41B8-89ED-2ED695098E11Q34880292-95C25E97-2425-4D1D-A1A5-B39A9FD68D79Q35923163-8D65925D-3687-4BF4-A08A-001F7E7D0B5DQ37575571-9FF8289A-F876-49A9-BCA1-E11D76A94A32Q37578702-6A612C2F-3F4B-4067-8F17-A062745FBB07Q37662933-59BEA8C0-AA0C-46E2-B724-4222E59559BBQ38152646-05F6CC95-213B-4E6D-AE48-C3F1A297EDC4Q38207111-9466926D-C11E-4A40-AF11-06258084F5E1Q38325814-B5ED8AE8-CC0F-4D90-BE73-8B48253A5F02Q38580461-F9AB830F-4480-4512-8AC9-951E851B18B2Q38592767-F7A0AB04-D571-48E3-9960-20DF570C7A4EQ38662765-E0E14E03-32D7-4398-8EF6-DF6EA89C3ACBQ38674739-D5C9FCF3-6D80-42DB-A60F-8D5DDBC2BE8AQ38674742-3602E726-B476-4FF9-A673-441D55222EB6Q38691457-D215C626-FC4E-4972-AC5C-802857150B5AQ38713765-56679BF7-DE4F-4EDB-9D84-97BE436F2869Q38739205-BEB86152-3277-4FEF-9C83-6515418375D1Q38747405-F065A93C-ACBA-4585-8E8B-5B7F73AD9648Q38748381-3B39B88B-E07C-46D3-A8BD-E3BB437F918DQ38752520-EFFE4B99-34B1-4E33-B6BE-D2A9E5BC5D08Q38758810-D8FB5000-833A-475C-A3D2-9222E1233A7DQ38768048-9CAF9EF5-9BD7-4A90-B303-2726C1FEDD1AQ38774861-3B1F8C16-2B6A-4FEF-854D-446B7AFCD4DFQ38778064-49E1C886-73ED-421A-927B-F7A8D2EC77A9
P2860
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@ast
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@en
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@nl
type
label
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@ast
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@en
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@nl
prefLabel
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@ast
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@en
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@nl
P2093
P2860
P50
P356
P1433
P1476
Dual peroxisome proliferator-a ...... in abdominally obese subjects.
@en
P2093
Benoit Noël
Bertrand Cariou
Martine Laville
Stéphanie Lambert-Porcheron
Valérie Sauvinet
Yassine Zaïr
P2860
P304
P356
10.2337/DC12-2012
P407
P577
2013-05-28T00:00:00Z